IL4 and neoplasm: Given this successful improvement of the stimulatory capacity of IL4 DCs, we subsequently showed that combining in situ downregulation of PD-L1 and PD-L2 with introduction of interleukin-15 transpresentation tools could further potentiate tumor-reactive T-cell expansion (19).